- Home
- FFAI vs ZNTL Comparison
FFAI vs ZNTL Comparison
Compare FFAI & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFAI
- ZNTL
- Stock Information
- Founded
- FFAI 2014
- ZNTL 2014
- Country
- FFAI United States
- ZNTL United States
- Employees
- FFAI N/A
- ZNTL N/A
- Industry
- FFAI
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- FFAI
- ZNTL Health Care
- Exchange
- FFAI NYSE
- ZNTL Nasdaq
- Market Cap
- FFAI 111.5M
- ZNTL 105.8M
- IPO Year
- FFAI N/A
- ZNTL 2020
- Fundamental
- Price
- FFAI $2.05
- ZNTL $1.37
- Analyst Decision
- FFAI
- ZNTL Buy
- Analyst Count
- FFAI 0
- ZNTL 7
- Target Price
- FFAI N/A
- ZNTL $8.60
- AVG Volume (30 Days)
- FFAI 12.0M
- ZNTL 1.4M
- Earning Date
- FFAI 08-13-2025
- ZNTL 08-08-2025
- Dividend Yield
- FFAI N/A
- ZNTL N/A
- EPS Growth
- FFAI N/A
- ZNTL N/A
- EPS
- FFAI N/A
- ZNTL N/A
- Revenue
- FFAI $853,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- FFAI $115,335.99
- ZNTL N/A
- Revenue Next Year
- FFAI N/A
- ZNTL N/A
- P/E Ratio
- FFAI N/A
- ZNTL N/A
- Revenue Growth
- FFAI 8.52
- ZNTL N/A
- 52 Week Low
- FFAI $0.83
- ZNTL $1.01
- 52 Week High
- FFAI $21.89
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- FFAI N/A
- ZNTL 53.19
- Support Level
- FFAI N/A
- ZNTL $1.29
- Resistance Level
- FFAI N/A
- ZNTL $1.43
- Average True Range (ATR)
- FFAI 0.00
- ZNTL 0.09
- MACD
- FFAI 0.00
- ZNTL 0.01
- Stochastic Oscillator
- FFAI 0.00
- ZNTL 77.02
About FFAI FARADAY FUTURE INTELLIGENT ELEC INC
Faraday Future Intelligent Electric Inc is a shared intelligent mobility ecosystem. The company is poised to break the boundaries between the Internet, IT, creative, and auto industries with product and service offerings that integrate new energy, AI, Internet, and sharing models. The company has additional engineering, sales, and operational capabilities in China and plans to develop its manufacturing capability in China through a joint venture.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.